ADAR and cancer: However, increasingly more genome-wide analyses suggest that a large proportion of the A-to-I edited sites are located inside intronic and UTR regions, indicating that, in cancer, the deregulation of ADAR1 involves a complex mechanism that may not be limited to A-to-I sites in this disease [4, 7, 20].